Impact of direct-acting antiviral (DAA) treatment for hepatitis C on pulmonary hemodynamics
T. Orizaga Franco (Barcelona, Spain), I. Blanco Vich (Barcelona, Spain), S. Slens (Barcelona, Spain), E. Alvarado (Barcelona, Spain), Z. Mariño (Barcelona, Spain), X. Torras (Barcelona, Spain), A. Baiges (Barcelona, Spain), F. Turon (Barcelona, Spain), V. Hernández-Gea (Barcelona, Spain), C. Villanueva (Barcelona, Spain), J. Moises (Barcelona, Spain), X. Forns (Barcelona, Spain), J. García-Pagán (Barcelona, Spain), J. Barberà Mir (Barcelona, Spain)
Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension
Disease area: Pulmonary vascular diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
T. Orizaga Franco (Barcelona, Spain), I. Blanco Vich (Barcelona, Spain), S. Slens (Barcelona, Spain), E. Alvarado (Barcelona, Spain), Z. Mariño (Barcelona, Spain), X. Torras (Barcelona, Spain), A. Baiges (Barcelona, Spain), F. Turon (Barcelona, Spain), V. Hernández-Gea (Barcelona, Spain), C. Villanueva (Barcelona, Spain), J. Moises (Barcelona, Spain), X. Forns (Barcelona, Spain), J. García-Pagán (Barcelona, Spain), J. Barberà Mir (Barcelona, Spain). Impact of direct-acting antiviral (DAA) treatment for hepatitis C on pulmonary hemodynamics. 1476
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
A case of acute interstitial pneumonia which developed during the interferon and ribavirin treatment for chronic hepatitis C Source: Eur Respir J 2005; 26: Suppl. 49, 84s Year: 2005
Risk of adverse effects of antitubercular drugs in patients with pulmonary tuberculosis and low active viral hepatitis C and other digestive tract diseases Source: Annual Congress 2008 - Tuberculosis in immigrants, disadvantaged populations, elderly, HIV-seropositives and in other risk groups Year: 2008
Successful hepatitis B treatment with lamivudine and interferon-alpha in a patient with cystic fibrosis Source: Eur Respir J 2004; 24: Suppl. 48, 617s Year: 2004
Effect of inhaled SNG001 (interferon-beta 1a) on sputum and blood antiviral biomarkers following a respiratory virus infection in asthmatic subjects Source: Annual Congress 2013 –Interesting cases of respiratory infections Year: 2013
Prevention of drug-induced liver injury in patients with pulmonary tuberculosis and chronic hepatitis C Source: International Congress 2019 – Clinical problems from non-malignant pleural disease to hypoventilation Year: 2019
The role of hepatitis C virus infections in idiopathic pulmonary fibrosis Source: Eur Respir J 2005; 26: Suppl. 49, 333s Year: 2005
The clinical flow and efficiency of treatment of pulmonary tuberculosis in patients with chorine organic pasticides and viral hepatitis ‘B‘ markers Source: Eur Respir J 2004; 24: Suppl. 48, 50s Year: 2004
Features the effectiveness of the treatment of moxifloxacin in patients with co-infections tuberculosis/HIV and hepatitis B,and/or C Source: Virtual Congress 2020 – Tuberculosis and comorbidities Year: 2020
The prevalence rate of chronic hepatitis B and C among pulmonary TB patients Source: Annual Congress 2008 - Tuberculosis in immigrants, disadvantaged populations, elderly, HIV-seropositives and in other risk groups Year: 2008
Pulmonary arterial hypertension in patients with HIV infection Source: Eur Respir Mon 2012; 57: 82-93 Year: 2012
Sarcoidosis associated with interferon-α therapy for chronic hepatitis C Source: Eur Respir J 2006; 28: Suppl. 50, 541s Year: 2006
The impact of bedaquiline and delamanid containing regimens on liver function in patients multi-infected with pulmonary DR-TB, HIV and viral hepatitis Source: International Congress 2019 – Tuberculosis: treatment and management Year: 2019
Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension Source: Eur Respir J 2004; 23: 321-326 Year: 2004
Impact of initial treatment strategy on long-term survival in pulmonary arterial hypertension (PAH) Source: International Congress 2018 – Risk stratification in treatment of pulmonary arterial hypertension Year: 2018
Influence of viral hepatitis and anti-TB drugs on hepatocyte disfunction in patients with MDR/XDR tuberculosis Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
Clinical-evolutive aspects of pulmonary tuberculosis at patients with chronic hepatitis Source: Annual Congress 2007 - Tuberculosis Year: 2007
Clinical and morphological outcomes of pulmonary tuberculosis concurrent with chronic hepatitis Source: Eur Respir J 2006; 28: Suppl. 50, 13s Year: 2006
Results of treatment of patients with pulmonary tuberculosis combined with HIV infection and hepatitis Source: International Congress 2018 – Tuberculosis comorbidities Year: 2018
Severe hepatitis associated with sitaxentan and response to glucocorticoid therapy Source: Eur Respir J 2009; 33: 1518-1519 Year: 2009
Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013